Recombinant multi-species BAK/BAK1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine BAK/BAK1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
The protein encoded by this gene belongs to the BCL2 protein family. BCL2 family members form oligomers or heterodimers and act as anti- or pro-apoptotic regulators that are involved in a wide variety of cellular activities. This protein localizes to mitochondria, and functions to induce apoptosis. It interacts with and accelerates the opening of the mitochondrial voltage-dependent anion channel, which leads to a loss in membrane potential and the release of cytochrome c. This protein also interacts with the tumor suppressor P53 after exposure to cell stress. [provided by RefSeq, Jul 2008]
The Alternative Names of target: Apoptosis regulator BAK,BAK,BAK-LIKE,BAK1,BCL2L7,Bak,Bak1,Bcl-2 homologous antagonist/killer,Bcl-2-like protein 7 (Bcl2-L-7),CDN1,N-BAK1,N-Bak
Go
to BAK/BAK1 products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-IP0150-Ag-1/ GM-Tg-hg-IP0150-Ag-2 | Human BAK/BAK1 protein | Human |
| GM-Tg-rg-IP0150-Ag-1/ GM-Tg-rg-IP0150-Ag-2 | Rat BAK/BAK1 protein | Rat |
| GM-Tg-mg-IP0150-Ag-1/ GM-Tg-mg-IP0150-Ag-2 | Mouse BAK/BAK1 protein | Mouse |
| GM-Tg-cynog-IP0150-Ag-1/ GM-Tg-cynog-IP0150-Ag-2 | Cynomolgus/Rhesus macaque BAK/BAK1 protein | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-IP0150-Ag-1/ GM-Tg-felg-IP0150-Ag-2 | Feline BAK/BAK1 protein | Feline |
| GM-Tg-cang-IP0150-Ag-1/ GM-Tg-cang-IP0150-Ag-2 | Canine BAK/BAK1 protein | Canine |
| GM-Tg-bovg-IP0150-Ag-1/ GM-Tg-bovg-IP0150-Ag-2 | Bovine BAK/BAK1 protein | Bovine |
| GM-Tg-equg-IP0150-Ag-1/ GM-Tg-equg-IP0150-Ag-2 | Equine BAK/BAK1 protein | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. |
GM-Tg-hg-IP0150-Ag-1/ GM-Tg-hg-IP0150-Ag-2;
GM-Tg-rg-IP0150-Ag-1/ GM-Tg-rg-IP0150-Ag-2;
GM-Tg-mg-IP0150-Ag-1/ GM-Tg-mg-IP0150-Ag-2; GM-Tg-cynog-IP0150-Ag-1/ GM-Tg-cynog-IP0150-Ag-2; GM-Tg-felg-IP0150-Ag-1/ GM-Tg-felg-IP0150-Ag-2; GM-Tg-cang-IP0150-Ag-1/ GM-Tg-cang-IP0150-Ag-2; GM-Tg-bovg-IP0150-Ag-1/ GM-Tg-bovg-IP0150-Ag-2; GM-Tg-equg-IP0150-Ag-1/ GM-Tg-equg-IP0150-Ag-2 |
| Products Name | BAK/BAK1 protein |
| Species | Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine |
| Target Name | BAK/BAK1 |
| Protein Sub-location | Introcelluar Protein |
| Isotypes | Recombinant protein |
| Expression platform | Mammalian cell |
| Bioactivity validation | Affintiy&bioactivity validated by ELISA, cell culture validated. |
| Tag | His |
| Products description | Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine BAK/BAK1 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
About Gmab

GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.